Company: PGEN
Filing Date: 2025-05-06
Form Type: PRE 14A
Source: 0001140361-25-017535
Chunk: 55

Company: PRECIGEN, INC.
Filing Date: 2025-05-06
Form: PRE 14A
Chunk 55
---
 contributed to its determination of payout amounts. The Compensation Committee considered the following specific achievements in 2024:

| • | The build-out of the Company’s Commercial team. |

| • | The completion of enrollment in the PRGN-3006 Phase 1b trial. |

| • | The reprioritization of PRGN-2009, utilizing NCI to enroll Phase 2 trials. |

| • | The various capital raises in 2024, including the $79 million preferred stock issuance in December 2024. |

The Compensation Committee discussed these accomplishments with Dr. Sabzevari and, subsequently, with members of the Board and the Compensation Committee’s independent compensation consultant, recommended to the Board the approval of the operational performance goals at 100% of target and of the clinical and financial performance goals at 100% of target. For non-Chief Executive Officer NEOs’ individual performance, all individuals were considered to have met their individual goals, with certain NEOs performing above expectations. Mr. Thomasian was awarded an additional 10% of his target bonus based on his leadership in raising additional capital during 2024. Mr. Shah was awarded an additional 25% of his target bonus based on his direct involvement in preparing, reviewing and submitting the BLA in 2024 along with his exemplary service to the Company through his involvement in other aspects of the Company’s day-to-day operations including supporting the capital raises in 2024 and his leadership in the Company’s manufacturing preparedness. Mr. Tennant was awarded an additional 2% of his target bonus based on his leadership in building the Company’s commercial operations. Taking into consideration the continued focus on enhanced equity ownership by our executives, as well as cash preservation, the Compensation Committee also approved the short-term incentive bonuses to be paid 100% in RSUs scheduled to vest in May 2025 based on the grant date fair market value of the Company’s shares, as reflected in the table below.

| Name                |     | Annual Target 
 Bonus (% of   
 Base Salary)  |     | Total Value of 
   Target Bonus 
            ($) |     | Aggregate     
 Achievement   
 Percentage of 
 Target        
 (%)           |     | Actual Cash 
 Payment     
 ($)         |     |      RSUs 
   Granted |     | Total Value of 
   Actual Bonus |
| Dr. Helen Sabzevari |     | 150%          |     |     $1,500,000 |     | 100%          |     | $—          |